Weiping Zou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1414328/publications.pdf

Version: 2024-02-01

161 papers	44,018 citations	6840 81 h-index	7836 155 g-index
163 all docs	163 docs citations	163 times ranked	52642 citing authors

#	Article	IF	Citations
1	IFNÎ³ signaling integrity in colorectal cancer immunity and immunotherapy. Cellular and Molecular Immunology, 2022, 19, 23-32.	4.8	57
2	CD8+ TÂcells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell, 2022, 40, 365-378.e6.	7.7	250
3	DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway. OncoImmunology, 2022, 11, 2052640.	2.1	4
4	Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Reports, 2022, 39, 110609.	2.9	46
5	Immune regulation in the tumor microenvironment and its relevance in cancer therapy. Cellular and Molecular Immunology, 2022, 19, 1-2.	4.8	14
6	Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discovery, 2021, 11, 1826-1843.	7.7	42
7	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nature Immunology, 2021, 22, 460-470.	7.0	50
8	IFNÎ± Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3661-3673.	3.2	6
9	Autophagy in tumour immunity and therapy. Nature Reviews Cancer, 2021, 21, 281-297.	12.8	185
10	Tissue-resident memory T cells in tumor immunity and immunotherapy. Journal of Experimental Medicine, 2021, 218, .	4.2	94
11	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell, 2021, 39, 480-493.e6.	7.7	71
12	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. Molecular Cancer Research, 2021, 19, 1571-1582.	1.5	8
13	LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nature Cell Biology, 2021, 23, 526-537.	4.6	96
14	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TÂcell immunity. Cancer Cell, 2021, 39, 973-988.e9.	7.7	93
15	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	5.7	52
16	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-Î³ (RORÎ³) Agonist for Use in Treating Cancer. Journal of Medicinal Chemistry, 2021, 64, 13410-13428.	2.9	11
17	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 2021, 27, 152-164.	15.2	451
18	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer. Cancer Research, 2021, 81, 5141-5143.	0.4	8

#	Article	IF	Citations
19	A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90. Oncogene, 2020, 39, 1347-1360.	2.6	15
20	Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. Gastroenterology, 2020, 158, 1417-1432.e11.	0.6	48
21	Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nature Cancer, 2020, 1, 1097-1112.	5.7	234
22	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature, 2020, 585, 277-282.	13.7	280
23	Introduction to the special issueâ€"Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment. Seminars in Immunology, 2020, 49, 101421.	2.7	1
24	Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy. Molecular Cell, 2020, 80, 384-395.	4.5	128
25	Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight, 2020, 5, .	2.3	59
26	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	3.9	112
27	Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry. Journal of Visualized Experiments, 2019, , .	0.2	9
28	LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. Nature Communications, 2019, 10, 3499.	5.8	233
29	Rewiring regulatory T cells for tumour killing. Nature Biomedical Engineering, 2019, 3, 766-767.	11.6	1
30	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. Annals of Surgical Oncology, 2019, 26, 2821-2830.	0.7	21
31	Immunotherapy in Ovarian Cancer. Surgical Oncology Clinics of North America, 2019, 28, 447-464.	0.6	27
32	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discovery, 2019, 9, 1673-1685.	7.7	566
33	CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor Î± in Active Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2019, 13, 905-915.	0.6	38
34	RORÎ³ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment. Cancer Immunology Research, 2019, 7, 1054-1063.	1.6	9
35	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research, 2019, 79, 3940-3951.	0.4	154
36	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019, 569, 270-274.	13.7	1,528

#	Article	IF	Citations
37	Cancer nanomedicine for combination cancer immunotherapy. Nature Reviews Materials, 2019, 4, 398-414.	23.3	658
38	A PHD in immunosuppression: oxygen-sensing pathways regulate immunosuppressive Tregs. Journal of Clinical Investigation, 2019, 129, 3524-3526.	3.9	5
39	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	15.2	3,421
40	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. Cancer Research, 2018, 78, 1751-1765.	0.4	30
41	Mechanistic insights into cancer immunity and immunotherapy. Cellular and Molecular Immunology, 2018, 15, 419-420.	4.8	30
42	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
43	Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight, 2018, 3, .	2.3	73
44	Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. Journal of Surgical Research, 2018, 232, 570-577.	0.8	16
45	Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecologic Oncology, 2018, 151, 1-3.	0.6	20
46	In Vitro Priming of Adoptively Transferred T Cells with a RORÎ³ Agonist Confers Durable Memory and Stemness In Vivo. Cancer Research, 2018, 78, 3888-3898.	0.4	30
47	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metabolism, 2018, 28, 87-103.e6.	7.2	263
48	Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. Journal of Immunology, 2018, 201, 814-820.	0.4	18
49	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.	13.5	400
50	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockadeâ€“mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	3.9	423
51	IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Research, 2017, 77, 2735-2745.	0.4	144
52	Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology, 2017, 17, 559-572.	10.6	1,448
53	Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nature Immunology, 2017, 18, 1332-1341.	7.0	508
54	Phenotype and tissue distribution of CD28H+ immune cell subsets. OncoImmunology, 2017, 6, e1362529.	2.1	13

#	Article	IF	Citations
55	ARID1A-mutated ovarian cancers depend on HDAC6Âactivity. Nature Cell Biology, 2017, 19, 962-973.	4.6	173
56	Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. Acta Pharmaceutica Sinica B, 2017, 7, 532-540.	5.7	3
57	Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell, 2017, 170, 548-563.e16.	13.5	1,377
58	Suppression of FIP200 and autophagy by tumor-derived lactate promotes naÃ¯ve T cell apoptosis and affects tumor immunity. Science Immunology, 2017, 2, .	5.6	83
59	The Role of Tumor Microenvironment in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 1036, 51-64.	0.8	124
60	Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. Journal of Clinical Investigation, 2017, 127, 4449-4461.	3.9	127
61	Regulatory T Cells in Tumor Immunity. , 2016, , 451-459.		2
62	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 2016, 76, 3156-3165.	0.4	224
63	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell, 2016, 165, 1092-1105.	13.5	340
64	LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer Discovery, 2016, 6, 784-801.	7.7	339
65	Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. OncoImmunology, 2016, 5, e1105430.	2.1	27
66	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
67	Synthetic RORÎ³ agonists regulate multiple pathways to enhance antitumor immunity. OncoImmunology, 2016, 5, e1254854.	2.1	68
68	Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. OncoImmunology, 2016, 5, e1074374.	2.1	147
69	Biological and pathological activities of interleukin-22. Journal of Molecular Medicine, 2016, 94, 523-534.	1.7	102
70	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Research, 2016, 76, 275-282.	0.4	204
71	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology, 2016, 17, 95-103.	7.0	310
72	Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. OncoImmunology, 2016, 5, e1082704.	2.1	29

#	Article	IF	Citations
73	Myeloid cells in hepatocellular carcinoma. Hepatology, 2015, 62, 1304-1312.	3.6	123
74	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
75	T Cell Fate in the Tumor Microenvironment. Cancer Drug Discovery and Development, 2015, , 53-74.	0.2	0
76	OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut, 2015, 64, 37-48.	6.1	55
77	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature, 2015, 527, 249-253.	13.7	897
78	Dendritic cells are stressed out in tumor. Cell Research, 2015, 25, 989-990.	5.7	4
79	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunology Research, 2015, 3, 1236-1247.	1.6	387
80	Depletion of androgen receptor (AR) in mesenchymal stem cells (MSCs) inhibits induction of CD4+CD25+FOX3+ regulatory T (Treg) cells via androgen TGF-Î² interaction. Journal of Applied Biomedicine, 2015, 13, 263-271.	0.6	2
81	Chemokines and cellular plasticity of ovarian cancer stem cells. Oncoscience, 2015, 2, 615-616.	0.9	11
82	MiR-194 Deregulation Contributes To Colorectal Carcinogenesis via Targeting AKT2 Pathway. Theranostics, 2014, 4, 1193-1208.	4.6	60
83	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
84	TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome. Clinical Cancer Research, 2014, 20, 4689-4704.	3.2	35
85	IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. Immunity, 2014, 40, 772-784.	6.6	309
86	Long Noncoding RNA GAPLINC Regulates CD44-Dependent Cell Invasiveness and Associates with Poor Prognosis of Gastric Cancer. Cancer Research, 2014, 74, 6890-6902.	0.4	248
87	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology, 2014, 147, 1393-1404.	0.6	529
88	ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nature Communications, 2014, 5, 4735.	5.8	55
89	MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Scientific Reports, 2014, 4, 6145.	1.6	54
90	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. Immunity, 2013, 39, 611-621.	6.6	366

#	Article	IF	Citations
91	NF-Î²B inhibits osteogenic differentiation of mesenchymal stem cells by promoting Î²-catenin degradation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9469-9474.	3.3	263
92	Th17 Cells in Cancer. , 2013, , 129-147.		0
93	T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Current Opinion in Immunology, 2013, 25, 214-221.	2.4	576
94	T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment. , 2013, , 17-44.		0
95	T Cells and Costimulation in Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 473-482.	1.0	22
96	Synbindin in Extracellular Signal-Regulated Protein Kinase Spatial Regulation and Gastric Cancer Aggressiveness. Journal of the National Cancer Institute, 2013, 105, 1738-1749.	3.0	31
97	Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. American Journal of Clinical Nutrition, 2013, 97, 1044-1052.	2.2	274
98	TLR2 Mediates Helicobacter pyloriâ€“Induced Tolerogenic Immune Response in Mice. PLoS ONE, 2013, 8, e74595.	1.1	47
99	Therapeutic Targeting Regulatory T Cells in Tumor. , 2013, , 585-602.		0
100	Bone marrow and the control of immunity. Cellular and Molecular Immunology, 2012, 9, 11-19.	4.8	256
101	Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. OncoImmunology, 2012, 1, 152-161.	2.1	123
102	Nine lives for TH9s?. Nature Medicine, 2012, 18, 1177-1178.	15.2	2
103	Interleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis. Cancer Research, 2012, 72, 420-429.	0.4	129
104	Th17 cells have stem cell-like features and promote long-term immunity. OncoImmunology, 2012, 1, 516-519.	2.1	45
105	Elevated Serum IL-8 Is Associated with the Presence of Hepatocellular Carcinoma and Independently Predicts Survival. Cancer Investigation, 2012, 30, 689-697.	0.6	27
106	Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2012, 56, 1342-1351.	3.6	388
107	Regulatory T Cells in Human Ovarian Cancer. Journal of Oncology, 2012, 2012, 1-7.	0.6	19
108	Targeting regulatory T cells. Targeted Oncology, 2012, 7, 15-28.	1.7	67

#	Article	IF	Citations
109	The B7 Homologues and their Receptors in Hematologic Malignancies. European Journal of Haematology, 2012, 88, 465-475.	1.1	17
110	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International Journal of Cancer, 2012, 130, 29-39.	2.3	230
111	Relationship Between Th17 and Regulatory T Cells in the Tumor Environment. , 2012, , 175-193.		0
112	Th17 cells in cancer: help or hindrance?. Carcinogenesis, 2011, 32, 643-649.	1.3	163
113	Deciphering the role of Th17 cells in human disease. Trends in Immunology, 2011, 32, 603-611.	2.9	201
114	T lymphocytes to IDO+ cells: check. Blood, 2011, 117, 2082-2083.	0.6	4
115	Dual biological effects of the cytokines interleukin-10 and interferon-Î³. Cancer Immunology, Immunotherapy, 2011, 60, 1529-1541.	2.0	129
116	Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. Journal of Translational Medicine, 2011, 9, 217.	1.8	28
117	Human T _H 17 Cells Are Long-Lived Effector Memory Cells. Science Translational Medicine, 2011, 3, 104ra100.	5.8	236
118	IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer. Journal of Immunology, 2011, 186, 4388-4395.	0.4	224
119	Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes and Development, 2011, 25, 1510-1527.	2.7	335
120	Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer. International Reviews of Immunology, 2011, 30, 120-126.	1.5	32
121	Response: Endogenous IL-17, tumor growth, and metastasis. Blood, 2010, 115, 2556-2557.	0.6	15
122	Prognostic significance of regulatory T cells in tumor. International Journal of Cancer, 2010, 127, 748-758.	2.3	94
123	TH17 cells in tumour immunity and immunotherapy. Nature Reviews Immunology, 2010, 10, 248-256.	10.6	531
124	A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease. Journal of Immunology, 2010, 185, 3866-3872.	0.4	47
125	Helicobacter pylori Immune Escape Is Mediated by Dendritic Cellâ€“Induced Treg Skewing and Th17 Suppression in Mice. Gastroenterology, 2010, 138, 1046-1054.	0.6	279
126	Role of T Cell TGFÎ² Signaling and IL-17 in Allograft Acceptance and Fibrosis Associated with Chronic Rejection. Journal of Immunology, 2009, 183, 7297-7306.	0.4	59

#	Article	IF	Citations
127	FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease. Cancer Research, 2009, 69, 3995-4000.	0.4	177
128	Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions. Cancer Research, 2009, 69, 8067-8075.	0.4	331
129	Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 2009, 114, 357-359.	0.6	354
130	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 2009, 114, 1141-1149.	0.6	688
131	Modeling dynamic changes in type 1 diabetes progression: Quantifying eta-cell variation after the appearance of islet-specific autoimmune responses. Mathematical Biosciences and Engineering, 2009, 6, 753-778.	1.0	20
132	Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008, 8, 467-477.	10.6	1,399
133	Tumor-Induced Immune Suppression ofIn vivoEffector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor Î². Cancer Research, 2008, 68, 5432-5438.	0.4	66
134	Induction of IL-17+ T Cell Trafficking and Development by IFN-Î³: Mechanism and Pathological Relevance in Psoriasis. Journal of Immunology, 2008, 181, 4733-4741.	0.4	433
135	Cutting Edge: IFN-Î³ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development. Journal of Immunology, 2008, 181, 5842-5846.	0.4	83
136	Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. Journal of Immunology, 2007, 178, 6730-6733.	0.4	375
137	Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Research, 2007, 67, 7487-7494.	0.4	147
138	Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation TreatToxoplasma gondiiandEncephalitozoon cuniculiInfection. Antimicrobial Agents and Chemotherapy, 2007, 51, 4324-4328.	1.4	27
139	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. Cancer Research, 2007, 67, 8900-8905.	0.4	294
140	Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. Journal of Immunology, 2007, 179, 1423-1426.	0.4	155
141	Blocking HDACs boosts regulatory T cells. Nature Medicine, 2007, 13, 1282-1284.	15.2	17
142	Regulatory T-cell compartmentalization and trafficking. Blood, 2006, 108, 426-431.	0.6	290
143	Manipulating T regulatory cells in cancer immunotherapy. Expert Review of Dermatology, 2006, 1, 589-597.	0.3	3
144	Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology, 2006, 6, 295-307.	10.6	1,810

#	Article	IF	Citations
145	Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. Journal of Immunology, 2006, 177, 40-44.	0.4	252
146	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	4.2	638
147	Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.. Liver International, 2005, 25, 580-594.	1.9	31
148	Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 2005, 5, 263-274.	12.8	1,858
149	Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. American Journal of Reproductive Immunology, 2005, 54, 369-377.	1.2	197
150	Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma. Cancer Research, 2005, 65, 5020-5026.	0.4	346
151	CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research, 2005, 65, 465-72.	0.4	295
152	Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals. Cancer Research, 2004, 64, 8451-8455.	0.4	395
153	Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. Cancer Research, 2004, 64, 5535-5538.	0.4	270
154	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	15.2	4,442
155	Blockade of B7-H1 improves myeloid dendritic cellâ€“mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	15.2	1,157
156	Toxoplasma gondii-Infected Human Myeloid Dendritic Cells Induce T-Lymphocyte Dysfunction and Contact-Dependent Apoptosis. Infection and Immunity, 2002, 70, 1750-1760.	1.0	57
157	Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. European Journal of Immunology, 2001, 31, 3833-3839.	1.6	41
158	Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 2001, 7, 1339-1346.	15.2	603
159	Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by Î²-Chemokines Rather Than IL-12. Journal of Immunology, 2000, 165, 4388-4396.	0.4	121
160	Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. Aids, 1999, 13, 455-463.	1.0	44
161	Administration of Interleukin 13 to Simian Immunodeficiency Virus-Infected Macaques: Induction of Intestinal Epithelial Atrophy. AIDS Research and Human Retroviruses, 1998, 14, 775-783.	0.5	5